BG-12 may become one of the best options to treat MS, with potential for $3 billion in annual sales, RBC Capital Markets says.
(Essdras M Suarez/Globe Staff/File 2008)
MASS. MOVERS
MS drug has big promise, study suggests
BG-12 may become one of the best options to treat MS, with potential for $3 billion in annual sales, RBC Capital Markets says.
(Essdras M Suarez/Globe Staff/File 2008)
Biogen Idec Inc., the world’s largest maker of multiple sclerosis medicines, gained the most in six months after the experimental MS pill BG-12 was shown to be safe and reduced the risk of relapse in a second late-stage trial. The study evaluated BG-12 and Copaxone, an injected treatment from Teva Pharmaceutical Industries Ltd. It found Biogen’s pill reduced the annual rate of relapse by 44 percent when taken twice daily, and by 51 percent when taken three times a day compared with placebo, meeting the trial goals, the Weston, Mass., company said.
For more from BostonGlobe.com, sign up or log in below
To continue, please sign up or log in to BostonGlobe.com
Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com
Sign up
Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.
Are you a Boston Globe home delivery subscriber?
Get FREE access as part of your print subscription.
BostonGlobe.com subscriber
Click to continue reading this article or to log in to BostonGlobe.com.
